Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Doug Robinson who wrote (70318)	4/21/1999 12:56:00 PM
From: Michaelste	Read Replies (1) \| Respond to of 119973

CEGE Cell Genesys Expands Research, License Pact With Miotix FOSTER CITY, Calif. (Dow Jones)--Cell Genesys Inc. (CEGE) and Mitotix Inc. agreed to expand their worldwide license and research collaboration to include cancer gene therapy. Financial terms were not disclosed. In a press release Wednesday, Cell Genesys said that under the 1998 collaboration, Cell Genesys exclusively licensed a series of cell cycle inhibitor genes used for the development of products for cardiovascular gene therapy from Mitotix. Cell Genesys will now have exclusive rights to these genes for cancer applications. Cell Genesys said it has observed that certain of these genes can induce tumor cell death in a wide range of cancers in laboratory studies and eliminate or inhibit the growth of human tumors in mice. Mitotix Inc. is a private biotechnology company. Cell Genesys develops and markets gene therapies to treat life-threatening diseases. (END) DOW JONES NEWS 04-21-99 12:54 PM